Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Docket		Date Filed	2014-06-02
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,395,767; 7,951,400; 8,628,799; RE44,186
Link to Docket	External link to docket

Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-02	1		Method.” The RE’186 patent is a reissue of U.S. Patent No. 6,395,767 (“the ’767 patent”), which issued on…RE44,186 (“the RE’186 patent”) and U.S. Patent No. 7,951,400 (“the ’400 patent”). 3. …expiration of the RE’186 patent and U.S. Patent No. 8,628,799 (“the ’799 patent”). … This is an action for patent infringement arising under the patent laws of the United States, … PATENTS-IN-SUIT 13. On April 30, 2013, the U.S. Patent and Trademark Office	External link to document
2014-09-23	21		than April 30, 2014. Date of Expiration of Patent: 7,951,400 (November 30, 2028); RE44,186 (July 31, 2023… Date of Expiration of Patent: 7,951,400 (November 30, 2028) … Amended Supplemental information for patent cases involving an Abbreviated New Drug Application… AMENDED SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG… 2 June 2014 1:14-cv-00696-GMS Patent None District Court, D. Delaware	External link to document
2014-11-05	26		2014, alleging patent infringement of U.S. Patent Nos. 7,951,400 ("the '400 Patent"), RE44,186…expiration of the '400 Patent, the '186 Patent, and the '799 Patent. (Id. iii! 1-3.) …RE44,186 ("the '186 Patent"), and 8,628,799 ("the '799 Patent"). (D.I. 1.) The … for a drug with patent protection triggered a statutory cause of action for patent holders. 8 Thus, … claimed in a patent or the use of which is claimed in a patent ... if the purpose	External link to document
2014-06-02	3		Date of Expiration of Patent: 7,951,400 (November 30, 2028) … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: 4/30/14. Date of Expiration of Patent: 11/30/28, 7/31/23, 7/13/25.Thirty Month Stay Deadline… X SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG… 2 June 2014 1:14-cv-00696-GMS Patent None District Court, D. Delaware	External link to document
2014-06-02	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE44,186; 7,951,400; 8,628,799;. (… 2 June 2014 1:14-cv-00696-GMS Patent None District Court, D. Delaware	External link to document